2-(1h-Imidazol-1-yl)benzenesulfonamide | 1094671-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1h-Imidazol-1-yl)benzenesulfonamide
• 英文别名: 2-imidazol-1-ylbenzenesulfonamide
• CAS: 1094671-87-0
• 化学式: C₉H₉N₃O₂S
• 分子量: 223.25
• InChiKey: PVZMUQOQLLVSKN-UHFFFAOYSA-N

物化性质

• 沸点：
  479.3±47.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES DE THIENYLE SUBSTITUES PRESENTANT UNE ACTIVITE DE DEACETYLASE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005014588A1

  公开（公告）日：2005-02-17

  A compound of formula (I): in which A represents optionally substituted monocyclic heteroaryl or phenyl B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl X and Y, which may be the same or different, each independently represent -0-, -NR1-, CO-, -S02-, -SO-, -S-, -NR1CO-, -NR1S02-, -CONR1-, -SO2NR1-, -NR1CONR1 or X may be a direct bond when Y represents -NR1-, -NR1CO-, -NR1SO2-, -CONR1-, - SO2NR1- or -NR1CONRI- provided that R1 represents alkyl substituted by -OR2, -NR3R4, - NR4COR5, -NR4SO2R5, -CONR3R4 or -S02NR3R4 R1 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR2, -NR3R4, -NR4COR5, -NR4S02R5, -CONR3R4 or -S02NR3R4 R2 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl R3 represents H or alkyl R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR3R4 represents a cyclic amine R5 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl n represents 0-3 m represents 1-3 p represents 0-3 and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.

  化合物的化学式（I）：其中A代表可选择取代的单环杂环芳基或苯基，B代表可选择取代的杂环芳基、芳基、芳基-融合-杂环烷基、杂环烷基-融合-环烷基、杂环烷基-融合-杂环烷基或芳基-融合-环烷基，X和Y，可以相同也可以不同，每个独立代表-0-、-NR1-、CO-、-SO2-、-SO-、-S-、-NR1CO-、-NR1SO2-、CONR1-、-SO2NR1-、-NR1CONR1或当Y代表-NR1-、-NR1CO-、-NR1SO2-、-CONR1-、-SO2NR1-或-NR1CONRI-时，X可以是直接键，条件是R1代表由-OR2、-NR3R4、NR4COR5、NR4SO2R5、CONR3R4或-S02NR3R4取代的烷基，R1代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基或由-OR2、-NR3R4、-NR4COR5、-NR4S02R5、-CONR3R4或-S02NR3R4取代的烷基，R2代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，R3代表H或烷基，R4代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，或NR3R4代表环胺，R5代表烷基、芳基、杂环芳基、环烷基、杂环烷基、芳基烷基、杂环芳基烷基、环烷基烷基、杂环烷基烷基，n代表0-3，m代表1-3，p代表0-3，以及相应的N-氧化物、药学上可接受的盐、溶剂合物和前药；以及用于治疗一种可以通过抑制组蛋白去乙酰化酶来预防、抑制或改善疾病的病理和/或症状的疾病。
• [EN] METHOD FOR PREVENTING OR TREATING AN OPTIC NEUROPATHY<br/>[FR] METHODE PERMETTANT DE PREVENIR OU DE TRAITER UNE NEUROPATHIE OPTIQUE
  申请人：PHARMACIA CORP

  公开号：WO2005021004A1

  公开（公告）日：2005-03-10

  The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.

  本发明提供了一种预防和/或治疗视神经病变的方法和组合物，包括Cox-2抑制剂和降低眼压的药剂。
• [EN] METHOD FOR THE TREATMENT OR PREVENTION OF RESPIRATORY DISORDERS WITH A CYCLOOXYGENASE-2 INHIBITOR IN COMBINATION WITH A MUSCARINIC RECEPTOR ANTAGONIST AND COMPOSITIONS THEREWITH<br/>[FR] PROCEDES DESTINES AU TRAITEMENT OU A LA PREVENTION DE TROUBLES RESPIRATOIRES AVEC UN INHIBITEUR DE CYCLOOXYGENASE-2 UTILISE EN COMBINAISON AVEC UN ANTAGONISTE DE RECEPTEUR MUSCARINIQUE ET COMPOSITION LES CONTENANT
  申请人：PHARMACIA CORP

  公开号：WO2005009340A2

  公开（公告）日：2005-02-03

  The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory disorder-related complications in a subject by administering to the subject at least one Cox-2 inhibitor in combination with one or more muscarinic receptor antagonists. Compositions, pharmaceutical compositions and kits are also described.
• [EN] METHOD FOR THE TREATMENT OR PREVENTION OF BONE DISORDERS WITH A CYCLOOXYGENASE-2 INHIBITOR ALONE AND IN COMBINATION WITH A BONE DISORDER TREATMENT AGENT AND COMPOSITIONS THEREWITH<br/>[FR] METHODE DE TRAITEMENT OU DE PREVENTION DES TROUBLES OSSEUX AU MOYEN D'UN INHIBITEUR DE CYCLOOXYGENASE-2 SEUL OU EN COMBINAISON AVEC UN AGENT DE TRAITEMENT DES TROUBLES OSSEUX, ET COMPOSITIONS ASSOCIEES
  申请人：PHARMACIA CORP

  公开号：WO2005020895A2

  公开（公告）日：2005-03-10

  The present invention describes a novel method for preventing or treating bone disorders and bone disorder-related complications in a subject involving a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a bone disorder treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a bone disorder treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.
• [EN] TREATMENT OR PREVENTION OF VASCULAR DISORDERS WITH COX-2 INHIBITORS IN COMBINATION WITH CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS<br/>[FR] TRAITEMENT OU PREVENTION DE TROUBLES VASCULAIRES AU MOYEN D'INHIBITEURS DE COX-2 ASSOCIEE A DES INHIBITEURS DE LA PHOSPHODIESTERASE SPECIFIQUE DE L'AMP CYCLIQUE
  申请人：PHARMACIA CORP

  公开号：WO2005020926A2

  公开（公告）日：2005-03-10

  A method is described for the prevention and/or treatment of vascular disorders and vascular disorder-related complications in a subject, the method comprising administering to the subject a Cox-2 inhibitor in combination with a cAMP-specific PDE inhibitor. Also described are therapeutic and pharmaceutical compositions and kits that are useful in the present invention.